Company Overview and News

 
Focus on Bandhan Bank, UltraTech, RCom results

2018-07-17 thehindubusinessline
Seventeen companies will declare their first quarter results of the current financial year on Wednesday. Among these are Artson Engineering, Bandhan Bank, Foseco India (second quarter and half-year results), GHCL, HT Media, JK Tyres & Industries, JM Financial, Mahindra CIE Automotive, Mastek, MindTree, NIIT Technologies, Pritish Nandy Communications, Responsive Industries, Reliance Communications, Sasken Technologies, UltraTech Cement and Warren Tea.
523405 NIITTECH FOSECOIND RESPONIND 505509 ARTSONEN HTMEDIA 532538 UCLQF 532712 532756 WARRENTEA ULTRACEMCO 500150 532387 532662 532541 RCOM UCLQY PNC 508494 MAHINDCIE 522134 JMFINANCIL

 
Warren Tea looks to expand hotel business

2018-05-23 livemint
Kolkata: Warren Tea Ltd, one of India’s oldest tea producers with seven prized tea estates in Assam, is looking to expand its hospitality business with substantial capital expenditure over the next three years, at a time of uncertainty, when plantation owners are faced with rising costs and contracting margins.
508494 WARRENTEA

 
NCLT wants Assam Co. bidding norms revised

2018-04-28 livemint
Kolkata: A suitor for Assam Co. India Ltd—the country’s oldest surviving and perhaps most prized tea company (in terms of assets), now going through insolvency resolution—has successfully petitioned the National Company Law Tribunal (NCLT) to dilute eligibility conditions for bids.
GOODRICKE 508494 538564 JAMESWARREN WARRENTEA 500166

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...